Advertisement

Effect of Hemoglobin Level on Long-Term All-Cause Mortality After Percutaneous Coronary Intervention in African-Americans

      Anemia has been shown to be an independent predictor of long-term mortality after percutaneous coronary intervention (PCI). African-Americans are known to have lower hemoglobin (Hgb) levels compared with Caucasians. The impact of anemia on long-term mortality in African-Americans undergoing PCI is unknown. We evaluated a total of 715 African-American patients (313 patients with anemia and 402 patients without anemia as defined by the World Health Organization [Hgb <13 g/dl for men and <12 g/dl for women]) using data from our bolus-only glycoprotein IIb/IIIa database. After a median follow-up of 3.2 years (interquartile range 2.4 to 3.8), there were a total of 72 (10%) deaths. Survival rate was 84% in the anemic group compared with 94% in the control group (hazard ratio [HR] 2.8, unadjusted p <0.001 by log-rank test). After adjustment for baseline clinical and procedural characteristics using a Cox proportional hazards model, Hgb as a dichotomous variable was a strong and independent predictor of all-cause mortality during the follow-up period (HR for death 2.0, 95% confidence interval 1.2 to 3.4, adjusted p = 0.012). Also, when Hgb was analyzed as a categorical variable having 3 groups with empirically determined cutoffs at <11.1, ≥11.1 to <12.7, and ≥12.7 g/dl, the effect remained significant (adjusted p = 0.008), with a HR of 2.3 for the group with lowest Hgb compared with the group with highest value (HR 2.6 for group with Hgb ≥11.1 to <12.7 compared with the group with the highest Hgb value). In conclusion, baseline Hgb is a strong and independent predictor of all-cause long-term mortality in African-Americans undergoing PCI.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reinecke H.
        • Trey T.
        • Wellmann J.
        • Heidrich J.
        • Fobker M.
        • Wichter T.
        • Walter M.
        • Breithardt G.
        • Schaefer R.M.
        Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions.
        Eur Heart J. 2003; 24: 2142-2150
        • McKechnie R.S.
        • Smith D.
        • Montoye C.
        • Kline-Rogers E.
        • O'Donnell M.J.
        • DeFranco A.C.
        • Meengs W.L.
        • McNamara R.
        • McGinnity J.G.
        • Patel K.
        • et al.
        • Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
        Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention.
        Circulation. 2004; 110s: 271-277
        • Nikolsky E.
        • Aymong E.D.
        • Halkin A.
        • Grines C.L.
        • Cox D.A.
        • Garcia E.
        • Mehran R.
        • Tcheng J.E.
        • Griffin J.J.
        • Guagliumi G.
        • et al.
        Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
        J Am Coll Cardiol. 2004; 44: 547-553
        • Perry G.S.
        • Byers T.
        • Yip R.
        • Margen S.
        Iron nutrition does not account for the hemoglobin differences between blacks and whites.
        J Nutr. 1992; 122: 1417-1424
        • Beutler E.
        • West C.
        Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume.
        Blood. 2005; 106: 740-745
        • Marmur J.D.
        • Poludasu S.
        • Agarwal A.
        • Vladutiu P.
        • Feit A.
        • Lapin R.
        • Cavusoglu E.
        Bolus-only platelet glycoprotein IIb–IIIa inhibition during percutaneous coronary intervention.
        J Invasive Cardiol. 2006; 18: 521-526
        • Marmur J.D.
        • Poludasu S.
        • Agarwal A.
        • Manjappa N.
        • Cavusoglu E.
        High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
        J Invasive Cardiol. 2008; 20: 53-58
        • Gottlieb S.S.
        Dead is dead—artificial definitions are no substitute.
        Lancet. 1997; 349: 662-663
        • Lauer M.S.
        • Blackstone E.H.
        • Young J.B.
        • Topol E.J.
        Cause of death in clinical research: time for a reassessment?.
        J Am Coll Cardiol. 1999; 34: 618-620
        • Curb J.D.
        • Ford C.E.
        • Pressel S.
        • Palmer M.
        • Babcock C.
        • Hawkins C.M.
        Ascertainment of vital status through the National Death Index and the Social Security Administration.
        Am J Epidemiol. 1985; 121: 754-766
      1. Nutritional Anaemias.
        World Health Organisation, Geneva1968 (9–10.)
        • Levey A.S.
        • Coresh J.
        • Balk E.
        • Kausz A.T.
        • Levin A.
        • Steffes M.W.
        • Hogg R.J.
        • Perrone R.D.
        • Lau J.
        • Eknoyan G.
        • National Kidney Foundation
        National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
        Ann Intern Med. 2003; 139: 137-147
        • Braunwald E.
        • Antman E.M.
        • Beasley J.W.
        • Califf R.M.
        • Cheitlin M.D.
        • Hochman J.S.
        • Jones R.H.
        • Kereiakes D.
        • Kupersmith J.
        • Levin T.N.
        • et al.
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)
        ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).
        Circulation. 2002; 106: 1893-1900
        • Bovill E.G.
        • Terrin M.L.
        • Stump D.C.
        • Berke A.D.
        • Frederick M.
        • Collen D.
        • Feit F.
        • Gore J.M.
        • Hillis L.D.
        • Lambrew C.T.
        Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction.
        Ann Intern Med. 1991; 115: 256-265
        • Lincoff A.M.
        • Bittl J.A.
        • Harrington R.A.
        • Feit F.
        • Kleiman N.S.
        • Jackman J.D.
        • Sarembock I.J.
        • Cohen D.J.
        • Spriggs D.
        • Ebrahimi R.
        • et al.
        • REPLACE-2 Investigators
        Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
        JAMA. 2003; 289: 853-863
        • Lin D.
        • Wei L.
        • Ying Z.
        Checking the Cox model with cumulative sums of martingale-based residuals.
        Biometrika. 1993; 80: 557-572
        • Cavusoglu E.
        • Chopra V.
        • Gupta A.
        • Clark L.T.
        • Eng C.
        • Marmur J.D.
        Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome.
        Am J Cardiol. 2006; 98: 580-584
        • Bunn H.F.
        Pathophysiology of the anemias.
        in: Isselbacher K.J. Braunwald E. Martin J.B. Fauci A.S. Wilson J.D. Kasper D.L. Harrison's Principles of Internal Medicine. 13th Ed. McGraw-Hill, New York1994: 1720-1721
        • Dillmann E.
        • Johnson D.G.
        • Martin J.
        • Mackler B.
        • Finch C.
        Catecholamine elevation in iron deficiency.
        Am J Physiol Regul Integr Comp Physiol. 1979; 237: R297-R300
        • Takahashi M.
        • Kurokawa S.
        • Tsuyusaki T.
        • Kikawada
        Studies of hyperkinetic circulatory state in chronic anemia.
        J Cardiol. 1990; 20: 331-339
        • Nikolsky E.
        • Mehran R.
        • Aymong E.D.
        • Mintz G.S.
        • Lansky A.J.
        • Lasic Z.
        • Negoita M.
        • Fahy M.
        • Pocock S.J.
        • Na Y.
        • et al.
        Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions.
        Am J Cardiol. 2004; 94: 1023-1027
        • Means R.T.
        Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia.
        Stem Cells. 1995; 13: 32-37
        • Gach O.
        • Legrand V.
        • Biessaux Y.
        • Chapelle J.P.
        • Vanbelle S.
        • Pierard L.A.
        Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris.
        Am J Cardiol. 2007; 99: 31-35
        • Husemann W.
        • Fobker M.
        • Pohlen M.
        • Bruch C.
        • Hausberg M.
        • Breithardt G.
        • Reinecke H.
        Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions.
        Nephrol Dial Transplant. 2007; 22: 2563-2570